Full profile
| Also known as | PS |
|---|---|
| Best for | Memory support · Cognitive load and stress |
| Evidence grade | Grade C — Limited — early or small human trials |
| Studied dose range | 100 mg two to three times daily (≈200–300 mg total) in many studies. |
| Time to effect | Often studied over several weeks of daily use. |
| Best form | Soy- or sunflower-derived PS with a stated milligram dose. |
Evidence, honestly graded
This is a wrong-source, wrong-population discount. The classic positive trials (Crook 1991, bovine-cortex PS; Kato-Kataoka 2010, soy-PS with a positive result only in a low-baseline subgroup) don't match what a modern label delivers to a healthy adult: a direct RCT of soy-derived PS at both 300 mg and 600 mg/day (Jorissen et al. 2001) failed to beat placebo on the primary cognitive measures in the target population. The FDA's own qualified health claim review for PS and cognitive function/dementia concluded there is "little scientific evidence" supporting the claim. Still a reasonable, well-tolerated inclusion, but the honest grade for soy/sunflower PS in a healthy adult is C, not B.
See the full grading rubric — study type, replication, population match, and dose adequacy — in The Evidence Standard.
Side effects
- Generally well tolerated
- Occasional GI upset or insomnia at higher doses
Who should avoid it or check first
- On blood-thinning medication without clinician review
- Pregnant or breastfeeding without guidance
Interactions
- May interact with blood thinners and anticholinergic medications — discuss with a clinician
Stacks well with
- Citicoline
- Bacopa Monnieri
What to look for on a label
- Check the elemental PS dose per serving.
- Sunflower-derived PS is an option for those avoiding soy.
References
- Kato-Kataoka A, Sakai M, Ebina R, et al. (2010). Journal of Clinical Biochemistry and Nutrition, 47(3):246–255Delayed verbal recall improved versus placebo in a low-baseline subgroup.
- Crook TH, Tinklenberg J, Yesavage J, et al. (1991). Neurology, 41(5):644–649Improved name-face and daily-task memory measures versus placebo.
- Jorissen BL, Brouns F, Van Boxtel MP, et al. (2001). Nutritional Neuroscience, 4(2):121–134No significant improvement over placebo on the primary cognitive measures at either dose.
- FDA qualified health claim decision — phosphatidylserine and cognitive function/dementia. FDA's own review of the evidence for a PS/cognition qualified health claim concluded there is "little scientific evidence" supporting it — the basis for grading soy/sunflower PS conservatively rather than trading on the older bovine-PS trials.
Primary citations for some entries above are still being compiled; those without a linked identifier are editorial summaries of the wider literature.
Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.
See how Phosphatidylserine compares on grade, dose, and goal in the Evidence Explorer.
